ArticleNeuropsychiatric disease and treatment2011
The importance of norepinephrine in depression.
Article in Neuropsychiatric disease and treatment, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
152 citing papers in PubMed, 6 syntheses or guidelines pooled it, 366 citations in OpenAlex.
- Effectiveness of indoor rock climbing and bouldering as treatment for depression - a systematic review.BMC psychiatry · 2025Pooled it
- Brain connectivity changes underlying depression and fatigue in relapsing-remitting multiple sclerosis: A systematic review.PloS one · 2024Pooled it
- Tryptophan modulation in individuals with attention deficit hyperactivity disorder: a systematic review.Journal of neural transmission (Vienna, Austria : 1996) · 2022Pooled it
- A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia.Molecular psychiatry · 2022Pooled it
- Dietary Inflammatory Potential and the Risk of Incident Depression in Adults: A Systematic Review.Advances in nutrition (Bethesda, Md.) · 2019Pooled it
- Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors.Human psychopharmacology · 2016Pooled it
- Effects of antidepressant medications on brain tissue microstructure in persistent depressive disorder across two randomized controlled trials.NeuroImage. Clinical · 2026Trial
- A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder.Translational psychiatry · 2023Trial
- Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study.Depression and anxiety · 2019Trial
- Ketamine influences the locus coeruleus norepinephrine network, with a dependency on norepinephrine transporter genotype - a placebo controlled fMRI study.NeuroImage. Clinical · 2018Trial
- Compartmental modeling of [(11)C]MENET binding to the norepinephrine transporter in the healthy human brain.Nuclear medicine and biology · 2016Trial
- Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.International clinical psychopharmacology · 2014Trial
- Gut microbiota-driven metabolites modulate the development of stress-related mental disorders.Translational psychiatry · 2026Review
- Capillary Electrophoresis With Amperometric Detection for Neurotransmitter Analysis: Principles, Electrode Materials, Methodologies, and Applications.Electrophoresis · 2026Review
- A review of animal-assisted therapy for older adults in Korea: effects on depression and cognitive function and implications for practice.Journal of animal science and technology · 2026Review
- Towards Mechanism-Informed Treatments for Mental Health.Journal of neurochemistry · 2026Review
- Article
- Antidepressant-Like Effects ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Intranasal (R)-ketamine modulates depression symptom and neurotransmitters-associated human brain connectivity.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Neurobiological mechanisms and brain network dysfunction in major depressive disorder: an integrative review.Frontiers in integrative neuroscience · 2026Review
92 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is one of the most common psychological diseases with significant potential morbidity and mortality. Although the underlying pathophysiology of depression has not been clearly defined, preclinical and clinical evidence suggest disturbances in serotonin (5-HT), norepinephrine (NE), and dopamine (DA) neurotransmission in the central nervous system. Virtually all currently available antidepressants act on one or more of the following mechanisms: inhibition of reuptake of 5-HT or NE (and DA), antagonism of inhibitory presynaptic 5-HT or NE receptors, or inhibition of monoamine oxidase. All of these mechanisms result in an enhanced neurotransmission of 5-HT and/or NE. Evidence for the involvement of NE in depression is abundant, and recent studies on neuronal pathways and symptoms highlight the specific role of NE in this disorder. NE plays a determinant role in executive functioning regulating cognition, motivation, and intellect, which are fundamental in social relationships. Social dysfunction is possibly one of the most important factors affecting the quality of life in depressed patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.